Last trading session Intellect Neurosciences, Inc. (OTC:ILNS) lost 22.58% of its value and closed at $0.0024 per share. About 106 million ILNS shares changed hands during the session.
On Dec. 27 the company came out with a press release announcing ILNS had obtained a pharmacokinetic profile report from a fourteen day safety trial for OX1 – the company’s lead Alzheimer’s candidate. The news seemed to have a profoundly positive effect on the stock as the price jumped 47.62% and the volume reached…